{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:09:05Z","timestamp":1768370945272,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-025-01390-x","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:33:28Z","timestamp":1768289608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab Plus Nanoparticle Polymeric Micellar Paclitaxel and S-1 as First-Line Treatment in HER2-Negative Advanced Gastric Cancer: A Real-World Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Yu-Qing","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Guo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"3","key":"1390_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"issue":"1","key":"1390_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0711-9","volume":"17","author":"L Di","year":"2017","unstructured":"Di L, Wu H, Zhu R, Li Y, Wu X, Xie R, et al. Multi-disciplinary team for early gastric cancer diagnosis improves the detection rate of early gastric cancer. BMC Gastroenterol. 2017;17(1):147. https:\/\/doi.org\/10.1186\/s12876-017-0711-9.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"1390_CR3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s10147-025-02792-4","volume":"30","author":"S Kanaji","year":"2025","unstructured":"Kanaji S, Urakawa N, Harada H, Ikeda T, Koterazawa Y, Aoki T, Sawada R, Otowa Y, Goto H, Hasegawa H, Yamashita K, Matsuda T, Kakeji Y. Multidisciplinary treatment for advanced gastric cancer. Int J Clin Oncol. 2025;30(7):1268\u201375. https:\/\/doi.org\/10.1007\/s10147-025-02792-4.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"1390_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2025;23(5):169\u201391. https:\/\/doi.org\/10.6004\/jnccn.2025.0022.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"9","key":"1390_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435\u201342. https:\/\/doi.org\/10.1200\/JCO.2007.13.9378.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1390_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28(9):1547\u201353. https:\/\/doi.org\/10.1200\/JCO.2009.25.4706.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"11","key":"1390_CR7","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.21873\/anticanres.16700","volume":"43","author":"M Yamamoto","year":"2023","unstructured":"Yamamoto M, Omori T, Shinno N, Hara H, Mukai Y, Sugase T, Takeoka T, Mikamori M, Kanemura T, Hasegawa S, Akita H, Haraguchi N, Nishimura J, Wada H, Matsuda C, Yasui M, Miyata H, Ohue M. Adjuvant chemotherapy with S-1 plus docetaxel versus S-1 plus oxaliplatin in stage III gastric cancer. Anticancer Res. 2023;43(11):5015\u201324. https:\/\/doi.org\/10.21873\/anticanres.16700.","journal-title":"Anticancer Res"},{"issue":"31","key":"1390_CR8","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.06.8429.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1390_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","volume":"140","author":"W Koizumi","year":"2014","unstructured":"Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319\u201328. https:\/\/doi.org\/10.1007\/s00432-013-1563-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"1390_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068974","volume":"8","author":"WW Chen","year":"2013","unstructured":"Chen WW, Wang F, Xu RH. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PloS one. 2013;8(7):e68974. https:\/\/doi.org\/10.1371\/journal.pone.0068974.","journal-title":"PloS one"},{"issue":"8884","key":"1390_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/0140-6736(93)92789-v","volume":"342","author":"J Liebmann","year":"1993","unstructured":"Liebmann J, Cook JA, Mitchell JB. Cremophor EL, solvent for paclitaxel, and toxicity. Lancet (London England). 1993;342(8884):1428. https:\/\/doi.org\/10.1016\/0140-6736(93)92789-v.","journal-title":"Lancet (London England)"},{"issue":"2","key":"1390_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10637-017-0506-4","volume":"36","author":"M Shi","year":"2018","unstructured":"Shi M, Sun J, Zhou J, Yu H, Yu S, Xia G, et al. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies. Invest New Drugs. 2018;36(2):269\u201377. https:\/\/doi.org\/10.1007\/s10637-017-0506-4.","journal-title":"Invest New Drugs"},{"issue":"3","key":"1390_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s12029-024-01058-y","volume":"55","author":"FY Wang","year":"2024","unstructured":"Wang FY, Huang XM, Cao YQ, Cao J, Ni J, Li K, et al. Nanoparticle polymeric micellar paclitaxel versus paclitaxel for patients with advanced gastric cancer. J Gastrointest Cancer. 2024;55(3):1105\u201310. https:\/\/doi.org\/10.1007\/s12029-024-01058-y.","journal-title":"J Gastrointest Cancer"},{"issue":"10294","key":"1390_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"2","key":"1390_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1390_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","volume":"22","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2019;22(4):828\u201337. https:\/\/doi.org\/10.1007\/s10120-018-00909-5.","journal-title":"Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"5","key":"1390_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.14986","volume":"29","author":"YY Wu","year":"2025","unstructured":"Wu YY, Shao H. Research progress of sintilimab in the treatment of cancer (Review). Oncol Lett. 2025;29(5):240. https:\/\/doi.org\/10.3892\/ol.2025.14986.","journal-title":"Oncol Lett"},{"issue":"21","key":"1390_CR18","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"issue":"12","key":"1390_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1390_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford England: 1990). 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"issue":"3","key":"1390_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/CAD.0000000000000735","volume":"30","author":"WC Que","year":"2019","unstructured":"Que WC, Huang YF, Lin XY, Lan YQ, Gao XY, Wang XL, Wu RP, Du B, Huang XB, Qiu HQ, Zhong DT. Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer. Anticancer Drugs. 2019;30(3):302\u20137. https:\/\/doi.org\/10.1097\/CAD.0000000000000735.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1390_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-007-0508-6","volume":"61","author":"CK Im","year":"2008","unstructured":"Im CK, Jeung HC, Rha SY, Yoo NC, Noh SH, Roh JK, et al. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(2):315\u201321. https:\/\/doi.org\/10.1007\/s00280-007-0508-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1390_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5301\/tj.5000665","volume":"104","author":"YQ Lan","year":"2018","unstructured":"Lan YQ, Wu RP, Huang XB, Wang XL, Zhong DT, Huang CY, Song JT. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer. Tumori. 2018;104(1):22\u20139. https:\/\/doi.org\/10.5301\/tj.5000665.","journal-title":"Tumori"},{"issue":"4","key":"1390_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/COC.0b013e3181e84b63","volume":"34","author":"F Wang","year":"2011","unstructured":"Wang F, Wang Z, Zhou N, An X, Xu R, He Y, et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol. 2011;34(4):401\u20135. https:\/\/doi.org\/10.1097\/COC.0b013e3181e84b63.","journal-title":"Am J Clin Oncol"},{"issue":"17","key":"1390_CR25","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752\u20136.","journal-title":"Cancer Res"},{"issue":"9","key":"1390_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2023.2238896","volume":"23","author":"M Noori","year":"2023","unstructured":"Noori M, Fayyaz F, Zali MR, Bashash D. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2023;23(9):1029\u201339. https:\/\/doi.org\/10.1080\/14737140.2023.2238896.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1390_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646355","volume":"11","author":"T Xie","year":"2021","unstructured":"Xie T, Zhang Z, Zhang X, Qi C, Shen L, Peng Z. Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: a systematic review and meta-analysis. Front Oncol. 2021;11:646355. https:\/\/doi.org\/10.3389\/fonc.2021.646355.","journal-title":"Front Oncol"},{"key":"1390_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1009254","volume":"13","author":"L Gu","year":"2022","unstructured":"Gu L, Huang T, Qiu S, Hong J, Fu R, Ni C, et al. Efficacy of PD-1\/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: an updated meta-analysis based on randomized controlled trials. Front Pharmacol. 2022;13:1009254. https:\/\/doi.org\/10.3389\/fphar.2022.1009254.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1390_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051543","volume":"15","author":"T Takeda","year":"2023","unstructured":"Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S, et al. Age-stratified analysis of first-line chemoimmunotherapy for extensive-stage small cell lung cancer: real-world evidence from a multicenter retrospective study. Cancers. 2023;15(5):1543. https:\/\/doi.org\/10.3390\/cancers15051543.","journal-title":"Cancers"},{"issue":"3","key":"1390_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/CAD.0000000000001554","volume":"35","author":"L Gao","year":"2024","unstructured":"Gao L, Tang L, Li X, Peng J, Hu Z, Liu B. Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer. Anticancer Drugs. 2024;35(3):277\u201383. https:\/\/doi.org\/10.1097\/CAD.0000000000001554.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"1390_CR31","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v17.i6.106361","volume":"17","author":"QX Chen","year":"2025","unstructured":"Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, et al. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg. 2025;17(6):106361. https:\/\/doi.org\/10.4240\/wjgs.v17.i6.106361.","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"1390_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/annonc\/mdp371","volume":"21","author":"W Koizumi","year":"2010","unstructured":"Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T, Miyashita K, Okada Y. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2010;21(4):766\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdp371.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01390-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:19:10Z","timestamp":1768342750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01390-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"29 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics Approval and Consent to Participate"}},{"value":"The study was approved by the Institutional Ethics Committee of Jiangsu Cancer Hospital, and was carried out in accordance with the principles of the Declaration of Helsinki(2024-07-01\/KY-2024-055).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}